Arcturus Therapeutics Holdings Inc (ARCT) - Total Liabilities
Based on the latest financial reports, Arcturus Therapeutics Holdings Inc (ARCT) has total liabilities worth $52.50 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore ARCT long-term investments to assets to see how much of total assets are deployed in long-term investments.
Arcturus Therapeutics Holdings Inc - Total Liabilities Trend (2011–2025)
This chart illustrates how Arcturus Therapeutics Holdings Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Arcturus Therapeutics Holdings Inc asset portfolio.
Arcturus Therapeutics Holdings Inc Competitors by Total Liabilities
The table below lists competitors of Arcturus Therapeutics Holdings Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sunfly Intelligent Technology Co Ltd
SHE:300423
|
China | CN¥1.24 Billion |
|
Lanpec Technologies Ltd
SHG:601798
|
China | CN¥1.16 Billion |
|
Zhuhai Kles Technology Co. Ltd. A
SHE:301314
|
China | CN¥90.16 Million |
|
ABG Sundal Collier Holding ASA
OL:ABG
|
Norway | Nkr5.63 Billion |
|
Bonree Data Technology Co Ltd
SHG:688229
|
China | CN¥52.56 Million |
|
Shanghai Laimu Electronics Co Ltd
SHG:603633
|
China | CN¥2.08 Billion |
|
Ambac Financial Group Inc
NYSE:AMBC
|
USA | $1.00 Billion |
|
Shoe Carnival Inc
NASDAQ:SCVL
|
USA | $485.68 Million |
Liability Composition Analysis (2011–2025)
This chart breaks down Arcturus Therapeutics Holdings Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Arcturus Therapeutics Holdings Inc balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.88 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Arcturus Therapeutics Holdings Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Arcturus Therapeutics Holdings Inc (2011–2025)
The table below shows the annual total liabilities of Arcturus Therapeutics Holdings Inc from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $57.16 Million | -44.55% |
| 2024-12-31 | $103.09 Million | -31.68% |
| 2023-12-31 | $150.89 Million | -16.21% |
| 2022-12-31 | $180.07 Million | +9.40% |
| 2021-12-31 | $164.60 Million | +106.00% |
| 2020-12-31 | $79.90 Million | +41.80% |
| 2019-12-31 | $56.35 Million | +84.42% |
| 2018-12-31 | $30.56 Million | +67.61% |
| 2017-12-31 | $18.23 Million | +320.05% |
| 2016-12-31 | $4.34 Million | +84.52% |
| 2015-12-31 | $2.35 Million | -0.97% |
| 2014-12-31 | $2.38 Million | +45.17% |
| 2013-12-31 | $1.64 Million | +113.02% |
| 2012-12-31 | $768.00K | +250.68% |
| 2011-12-31 | $219.00K | -- |
About Arcturus Therapeutics Holdings Inc
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 cli… Read more